Filing Analysis
Aprea Therapeutics, Inc. issued an 8-K to announce the expansion of its intellectual property portfolio related to its precision oncology programs.
📋 Key Facts
- Announcement date: August 28, 2026
- Subject matter: Expansion of intellectual property portfolio for precision oncology programs
- The filing includes a press release as Exhibit 99.1
Aprea Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the periods ended June 30, 2026, and provided an updated corporate presentation.
📋 Key Facts
- Announced financial results for the three and six months ended June 30, 2026 (Item 2.02).
- Issued an update on Company operations via press release dated August 12, 2026.
- Updated its corporate presentation slide deck (Exhibit 99.2).
Aprea Therapeutics has received a second extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement. The company now has until January 19, 2027, to maintain a closing bid price of at least $1.00 for 10 consecutive business days to avoid delisting.
🚩 Red Flags
- Failure to regain compliance during the initial 180-day period (which expired July 22, 2026).
- Ongoing risk of delisting from Nasdaq if the $1.00 threshold is not met by January 2027.
- Persistent low stock price indicates market lack of confidence or significant dilution/capital issues.
📋 Key Facts
- Received notification from Nasdaq on July 23, 2026, regarding failure to meet the Minimum Bid Price Requirement (Nasdaq Listing Rule 5550(a)(2)).
- The company was granted a 'Second Compliance Period' of 180 calendar days.
- The new deadline to demonstrate compliance is January 19, 2027.
- Compliance requires the stock to close at $1.00 or higher for at least 10 consecutive business days.
Aprea Therapeutics entered into a securities purchase agreement to conduct a private placement of common stock and warrants, expected to raise approximately $3.1 million in gross proceeds. The offering includes pre-funded warrants and common warrants with an exercise price of $1.04 per share.
🚩 Red Flags
- Significant dilution: Issuance of over 2.6 million common stock equivalents (warrants) alongside existing equity.
- Insider involvement: The filing notes that 'Company insiders' are among the purchasers.
- Restrictive covenants: The company is prohibited from issuing other equity or entering variable rate transactions for 120-180 days following registration effectiveness.
📋 Key Facts
- Expected aggregate gross proceeds: approximately $3.1 million.
- Issuance of 2,623,023 shares (Common Stock or Pre-Funded Warrants) and 2,623,023 Common Warrants.
- Combined effective offering price per unit: $1.165.
- Common Warrants exercise price: $1.04 per share; exercisable for 5 years.
- Closing date expected by December 10, 2025.
- Maxim Group LLC acting as placement agent with a 7% cash fee and warrants representing 5% of the total shares issued.
Aprea Therapeutics issued an 8-K to announce its quarterly financial results for the periods ended September 30, 2025. The filing also includes an updated corporate presentation deck.
📋 Key Facts
- Announced financial results for the three and nine months ended September 30, 2025.
- Provided an operational update for the same period.
- Updated the company's corporate presentation slide deck (Exhibit 99.2).
Aprea Therapeutics issued a clinical update regarding its ACESOT-1051 trial. The company reported early signals of activity for its WEE1 Kinase Inhibitor, APR-1051.
📋 Key Facts
- Clinical update released on October 24, 2025.
- Trial name: ACESOT-1051.
- Drug candidate: WEE1 Kinase Inhibitor APR-1051.
- Reported early signals of activity in the trial.
Aprea Therapeutics announced a strategic pivot in its clinical development program for ATRN-119, including the pausing of enrollment in current dosing arms and a shift toward exploring combination therapies. The company also updated its corporate presentation to reflect these developments.
🚩 Red Flags
- Pausing clinical trial enrollment for current dosing regimens often indicates efficacy or safety concerns discovered during data review.
- Strategic shift toward 'combination therapies' suggests the monotherapy approach may not have met primary objectives or required optimization.
📋 Key Facts
- Announced recommended Phase 2 dosing for ATRN-119 on October 15, 2025.
- Paused further enrollment in both once daily and twice daily dosing arms of ABOYA-119.
- Company is considering the future development of ATRN-119 specifically in combination therapies.
Aprea Therapeutics, Inc. has filed an 8-K to update its corporate presentation slide deck as of September 8, 2025.
📋 Key Facts
- The company updated its corporate presentation slide deck (Exhibit 99.1).
- Filing date: September 8, 2025.
Aprea Therapeutics issued an 8-K to announce its quarterly financial results for the periods ended June 30, 2025. The company also updated its corporate presentation deck.
📋 Key Facts
- Announced financial results for the three and six months ended June 30, 2025.
- Provided an operational update corresponding to the same period.
- Updated the Company's corporate presentation slide deck (Exhibit 99.2).
Aprea Therapeutics reported the results of its 2025 annual meeting of stockholders held on June 5, 2025. The meeting included elections for three Class III directors and ratification of the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 5, 2025.
- Election of Jean-Pierre Bizzari, M.D., Oren Gilad, Ph.D., and John B. Henneman III to Class III directors until the 2028 Annual Meeting.
- Ratification of EisnerAmper LLP as independent registered public accounting firm for fiscal year 2025.
- Quorum was established with 3,817,718 shares (69.09%) represented out of 5,525,172 total voting shares.
- Non-binding advisory votes regarding executive compensation and frequency of votes were conducted.
Aprea Therapeutics issued an 8-K to announce its quarterly financial results for the period ending March 31, 2025. The filing also includes an updated corporate presentation deck.
📋 Key Facts
- Announced financial results for the three months ended March 31, 2025 (Item 2.02).
- Provided an operational update for the same period via press release.
- Updated its corporate presentation slide deck as of May 14, 2025 (Item 8.01).
Aprea Therapeutics, Inc. announced its financial results for the period ending December 31, 2024, and updated its corporate presentation. Additionally, the company amended an employment agreement for John P. Hamill to increase severance benefits in the event of termination without cause or resignation for good reason.
🚩 Red Flags
- Increased executive severance packages can be viewed as a defensive measure or an increased cash liability in the event of leadership turnover.
📋 Key Facts
- Company released financial results for the three and twelve months ended December 31, 2024 (Item 2.02).
- Amended employment agreement for John P. Hamill effective March 25, 2025.
- Severance benefits for Mr. Hamill increased from 9 months to 12 months of base salary and COBRA coverage in the event of termination without cause or good reason.
- In a change of control scenario, severance increases from 12 months to 18 months of base salary plus COBRA coverage.
- Updated corporate presentation slide deck released (Exhibit 99.2).
Aprea Therapeutics, Inc. issued an 8-K to announce a press release regarding an update to its existing patent portfolio.
📋 Key Facts
- The company issued a press release on February 5, 2025, concerning updates to its patent portfolio.
- The filing is categorized under Item 8.01 (Other Events).
Aprea Therapeutics released an updated corporate presentation disclosing its preliminary cash position as of year-end 2024. The company reported a cash and cash equivalents balance of $22.8 million.
🚩 Red Flags
- Financial figures are unaudited and subject to change upon completion of fiscal year 2024 statements.
📋 Key Facts
- As of December 31, 2024, the Company had a cash and cash equivalents balance of $22,800,000.
- The reported financial information is unaudited and preliminary.
- The disclosure was made via an updated corporate presentation slide deck.
Aprea Therapeutics entered into an 'at the market' (ATM) offering agreement with H.C. Wainwright & Co., LLC to sell up to $3.0 million in common stock. The proceeds are intended for general corporate purposes, specifically preclinical studies and clinical trials.
🚩 Red Flags
- Potential dilution for existing shareholders through the ATM offering.
- Small offering size ($3M) relative to typical biotech burn rates may indicate a need for continuous capital infusion.
📋 Key Facts
- Entered into Sales Agreement with H.C. Wainwright & Co., LLC on November 8, 2024.
- Aggregate offering price of up to $3.0 million in common stock.
- Commission rate for the agent is 3.0% of gross proceeds.
- Proceeds earmarked for preclinical studies, clinical trials, and product candidate advancement.
Aprea Therapeutics issued an 8-K to announce its financial results for the third quarter ended September 30, 2024, and provided a corporate presentation update.
📋 Key Facts
- Reported financial results for the three months ended September 30, 2024.
- Released an updated corporate presentation slide deck (Exhibit 99.2).
- Filed under Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events).
Aprea Therapeutics announced the presentation of preliminary safety results for its WEE1 inhibitor, APR-1051, at the EORTC-NCI-AACR Symposium in Barcelona.
📋 Key Facts
- Company is presenting preliminary safety results on APR-1051 (WEE1 inhibitor).
- Presentation occurred at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.
- The disclosure was made via a press release incorporated by reference.
Aprea Therapeutics announced the departure of its Chief Medical Officer, Dr. Nadeem Mirza, effective October 9, 2024, and the appointment of Phillipe Pultar, MD, as Senior Medical Advisor. The company also provided preliminary cash position updates for the quarter ended September 30, 2024.
🚩 Red Flags
- Sequential decrease in cash and cash equivalents (from $28.7M to $26.2M).
- Departure of a key executive (CMO) during the quarterly closing process.
📋 Key Facts
- Dr. Nadeem Mirza is stepping down as Chief Medical Officer effective October 9, 2024.
- Dr. Mirza will remain with the company through at most December 13, 2024, to facilitate transition.
- Phillipe Pultar, MD, has been engaged as Senior Medical Advisor.
- Preliminary cash and cash equivalents expected to be ~$26.2 million as of Sept 30, 2024.
- Cash position decreased from ~$28.7 million on June 30, 2024.
Aprea Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ending June 30, 2024, and updated its corporate presentation slide deck.
📋 Key Facts
- Announced financial results for the three months ended June 30, 2024 via press release (Exhibit 99.1).
- Updated its corporate presentation slide deck as of August 12, 2024 (Exhibit 99.2).
- The filing is categorized under Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events).
Aprea Therapeutics held its 2024 annual meeting of stockholders on June 20, 2024. The meeting resulted in the election of three Class II directors and the ratification of EisnerAmper LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 20, 2024.
- Quorum reached with 3,826,179 shares (approx. 70.46%) of 5,430,215 total voting shares represented.
- Elected Michael Grissinger, Gabriela Gruia, M.D., and Rifat Pamukcu, M.D. to the Board of Directors for terms ending at the 2027 Annual Meeting.
- Ratified the appointment of EisnerAmper LLP as independent registered public accounting firm for fiscal year 2024 with 3,788,888 votes in favor.
Aprea Therapeutics announced a clinical milestone regarding its oral WEE1 inhibitor, APR-1051. The company has successfully dosed the first patient in the ACESOT-1051 Phase 1 trial.
📋 Key Facts
- First patient was dosed in the ACESOT-1051 Phase 1 clinical trial on June 17, 2024.
- The trial is evaluating APR-1051, an oral WEE1 inhibitor.
- Company updated its corporate presentation slide deck as of June 2024.
Aprea Therapeutics, Inc. filed an 8-K to announce its quarterly financial results for the period ending March 31, 2024 and provided an updated corporate presentation.
📋 Key Facts
- Announced financial results for the three months ended March 31, 2024 via press release (Exhibit 99.1).
- Updated its corporate presentation slide deck as of May 14, 2024 (Exhibit 99.2).
- The filing is categorized under Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events).
Aprea Therapeutics issued an 8-K to announce four upcoming poster presentations at the American Association of Cancer Research (AACR) Annual Meeting and provided an updated corporate presentation slide deck.
📋 Key Facts
- Company plans to present four poster presentations at the AACR Annual Meeting.
- Updated corporate presentation slide deck was released on April 10, 2024.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation).
Aprea Therapeutics issued an 8-K to announce its financial results for the three and twelve months ended December 31, 2023, and provided a corporate presentation update.
📋 Key Facts
- Announced financial results for the periods ending December 31, 2023 (three and twelve months).
- Released an updated corporate presentation slide deck dated March 2024.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation).
Aprea Therapeutics entered into a $16 million private placement agreement to issue common stock and various warrants, while simultaneously terminating an existing at-the-market (ATM) offering with H.C. Wainwright & Co.
🚩 Red Flags
- Significant potential dilution from multiple tranches of warrants (Tranche A and B).
- Termination of a previous ATM offering suggests a shift in financing strategy or preference for this specific private placement.
- Complexity of warrant structures with price-based triggers can lead to volatility.
📋 Key Facts
- Entered into a Securities Purchase Agreement on March 11, 2024.
- Expected aggregate gross proceeds from the private placement: approximately $16.0 million.
- Potential future warrant cash exercise gross proceeds: approximately $18.0 million.
- Issuance of 1,687,712 shares at $7.29 per share.
- Includes Pre-Funded Warrants (up to 507,076 shares), Tranche A Warrants (up to 1,097,394 shares), and Tranche B Warrants (up to 1,097,394 shares).
- Tranche A/B warrants have specific price-based triggers ($14.58 and $18.225 respectively) linked to Phase 2 dose announcements.
- Terminated an existing Sales Agreement with H.C. Wainwright & Co., LLC effective March 11, 2024.
Aprea Therapeutics, Inc. filed an 8-K to announce the update of its corporate presentation slide deck as of February 6, 2024.
📋 Key Facts
- The company updated its corporate presentation slide deck (Exhibit 99.1).
- Filing date: February 6, 2024.
Aprea Therapeutics provided preliminary, unaudited estimates of its cash position as of December 31, 2023. The company reported approximately $21.6 million in total cash, cash equivalents, and restricted cash.
🚩 Red Flags
- Preliminary/unaudited nature of the reported cash position (subject to change).
📋 Key Facts
- Preliminary cash, cash equivalents, and restricted cash balance: ~$21.6 million as of Dec 31, 2023.
- The financial results are unaudited and subject to change upon completion of year-end closing procedures.
- The company is an emerging growth company.
Aprea Therapeutics entered into an 'at the market' (ATM) offering agreement with H.C. Wainwright & Co., LLC to sell up to $1.0 million in common stock. The proceeds are intended for general corporate purposes, specifically preclinical studies and clinical trials.
🚩 Red Flags
- Potential dilution for existing shareholders through the issuance of new common stock.
- Small offering size ($1M) relative to typical biotech burn rates may indicate a need for continuous capital infusions (though not explicitly stated as a going concern).
📋 Key Facts
- Entered into a Sales Agreement with H.C. Wainwright & Co., LLC on January 26, 2024.
- Aggregate offering price of up to $1.0 million in common stock.
- The offering will be conducted via an 'at the market' method pursuant to a Form S-3 registration statement filed on Jan 26, 2024.
- Commission for H.C. Wainwright & Co., LLC is set at 3.0% of gross proceeds.
- Proceeds are earmarked for preclinical studies, clinical trials, and product candidate advancement.
Aprea Therapeutics issued an 8-K to announce a corporate update regarding its development plans for 2024 and released an updated corporate presentation.
📋 Key Facts
- Filed on January 4, 2024.
- Company announced corporate updates and development plans for the year 2024.
- Updated corporate presentation slide deck was released as Exhibit 99.2.